Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.

摘要: Fifty-eight patients harboring recurrent malignant brain tumors were evaluated. CCNU (110 mg/m2) was administered on Day 1, procarbazine (60 daily for 14 days beginning 8, and vincristine (1.4 Days 8 29 of each 6-week cycle therapy. Therapy continued until tumor progression documented. Before course, a neurologic examination performed radionuclide computerized tomographic scans obtained. Response defined as improvement or deterioration, respectively, in at least two the three tests. Of 46 gliomas, 12 (26%) responded to therapy, 18 (39%) had progression, 16 (35%) disease stability. Nineteen not previously treated with another form chemotherapy: eight (42%) stability, only (16%) early progression. The median time 26 weeks responding therapy having Approximately 30% alive without evidence 1 year. Evaluated by rate response stabilization, this combination similar BCNU-5-fluorouracil used glioma.